OverviewSuggest Edit

NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. The Company offers find-io platform which allows to identify proteins that can be targeted with immunomedicines to repair and maintain anti-tumor immunity,  to assess immune pathways in both primary immune cells and established cell lines from immune lineages.
TypePublic
Founded2015
HQBeltsville, MD, US
Websitenextcure.com
Employee Ratings1.5

Latest Updates

Revenue (FY, 2020)$22.4 M(+253%)
Share Price (Sept 2021)$7.3(-4%)
Cybersecurity ratingBMore

Key People/Management at NextCure

Elaine V. Jones

Elaine V. Jones

Director
David Kabakoff

David Kabakoff

Chairman
Chau Q. Khuong

Chau Q. Khuong

Director
Steven P. Cobourn

Steven P. Cobourn

CFO
Michael Richman

Michael Richman

President & CEO and Director
Linda Liu

Linda Liu

Senior Vice President, Research
Show more

NextCure Office Locations

NextCure has an office in Beltsville
Beltsville, MD, US (HQ)
9000 Virginia Manor Rd #200
Show all (1)

NextCure Financials and Metrics

NextCure Revenue

NextCure's revenue was reported to be $22.38 m in FY, 2020
USD

Net income (Q2, 2021)

(18.0m)

EBIT (Q2, 2021)

(18.0m)

Market capitalization (8-Sept-2021)

201.6m

Closing stock price (8-Sept-2021)

7.3

Cash (30-Jun-2021)

34.9m

EV

169.3m
NextCure's current market capitalization is $201.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.3m22.4m

General and administrative expense

2.6m3.4m9.6m17.0m

R&D expense

13.0m19.8m34.2m46.6m

Operating expense total

15.5m23.2m43.8m63.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

1.4m1.4m1.6m22.4m

General and administrative expense

1.7m2.7m2.6m3.6m4.7m4.7m4.8m6.0m

R&D expense

6.5m7.6m8.7m10.6m11.1m12.7m12.4m11.9m

Operating expense total

8.2m10.4m11.3m14.2m15.8m17.4m17.2m18.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.4m135.2m34.1m32.8m

Prepaid Expenses

133.0k152.0k3.7m2.8m

Current Assets

9.4m135.8m340.0m288.0m

PP&E

10.0m11.4m12.1m15.8m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(15.5m)(22.8m)(33.7m)(36.6m)

Depreciation and Amortization

582.0k1.7m3.4m

Accounts Payable

767.0k1.3m(622.0k)2.0m

Cash From Operating Activities

(12.5m)8.0m(35.6m)(45.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(6.2m)(14.4m)(22.8m)9.7m(4.8m)(21.1m)(16.5m)(34.5m)

Depreciation and Amortization

563.0k1.1m1.9m751.0k1.5m2.4m1.1m3.0m

Accounts Payable

455.0k(493.0k)93.0k402.0k574.0k(1.7m)(1.9m)(2.5m)

Cash From Operating Activities

(7.1m)(17.7m)(25.6m)(10.6m)(23.0m)(38.7m)(13.9m)(31.1m)
USDFY, 2017

Financial Leverage

-0.8 x
Show all financial metrics

NextCure Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

NextCure Online and Social Media Presence

Embed Graph

NextCure News and Updates

NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the…

NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in…

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical tr…

NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in th…

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in …

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investiga…
Show more

NextCure Blogs

NextCure Reports Second Quarter 2021 Financial Results

NextCure Reports Second Quarter 2021 Financial Results Content Import Thu, 08/05/2021 - 16:10 NextCure Reports Second Quarter 2021 Financial Results August 5, 2021 at 4:05 PM EDT This release is a backfill from a News Wire Earnings BE…

NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit

BELTSVILLE, Md. , April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in

NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference

NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference Content Import Wed, 04/07/2021 - 16:06 NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference April 7, 2021 at 4:05 PM EDT This release is a backfill from a News…

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

BELTSVILLE, Md. , March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors Content Import Mon, 09/14/2020 - 16:05 NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors September 14, 2020 at 4:05 PM EDT This release is a b…

NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference

BELTSVILLE, Md. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the
Show more

NextCure Frequently Asked Questions

  • When was NextCure founded?

    NextCure was founded in 2015.

  • Who are NextCure key executives?

    NextCure's key executives are Elaine V. Jones, David Kabakoff and Chau Q. Khuong.

  • What is NextCure revenue?

    Latest NextCure annual revenue is $22.4 m.

  • Who are NextCure competitors?

    Competitors of NextCure include Burning Rock Biotech, Luye Pharma and Oblique Therapeutics.

  • Where is NextCure headquarters?

    NextCure headquarters is located at 9000 Virginia Manor Rd #200, Beltsville.

  • Where are NextCure offices?

    NextCure has an office in Beltsville.

  • How many offices does NextCure have?

    NextCure has 1 office.